Olanzapine for Opioid Use Disorder

"Olanzapine is an effective antipsychotic for treating delusional parasitosis, as well as other psychiatric conditions such as delirium or unipolar depression."

"The clinical trial appears to be searching for volunteers, as seen on clinicaltrials.gov. This specific trial was originally posted on 7/28/2022 and updated last on 8/8/2022."

"This study is looking for 48 participants that fit the following criteria: they must be aged 18 to 65, have a history of opioid abuse, and (for female patients) either be unable to bear children or on highly effective birth control. Additionally, all potential subjects should exhibit symptoms of SMI."

"As of right now, there are 21 ongoing Olanzapine trials in 402 cities across 8 nations. The first-ever clinical trial for this medication was completed in 2007 by Eli Lilly and Company. It only involved 20 patients and stopped at the N/A stage of drug approval . In the 14 years since then, 211 similar studies have been carried out."

"While there is safety data for Olanzapine, it only exists in a Phase 2 trial format. Efficacy has not been proven yet, so the Power team gave it a score of 2."

"That is correct. The clinical trial in question, which was posted on July 28th, 2020 and edited on August 8th, 2020, is still recruiting patients according to the information available on clinicaltrials.gov. They are looking for a total of 48 participants that will be spread across 2 sites."

"Right now, there are a total of 21 different studies investigating olanzapine. Out of those, 5 are currently in phase 3. Although the majority of research is based out of Kansas City, Missouri, 709 other research locations are also running similar investigations."

"Out of the 298 clinical trials available, this is one of 26 that are meant for patients under 18 years old and one of 262 for people over 65."